PGX-0100

AXP000239.1 · Phage therapy

Platform
phage cocktail spray
Originator
Precisio Biotix Therapeutics
Sponsor
Precisio Biotix Therapeutics

Names

NameTypeSource
PGX-0100preferred name, codecurator, ctgov
phage cocktail-SPKsynonymctgov

Virus

Role
Phage
Family
Caudoviricetes
Virus
bacteriophage cocktail of 14 phages against S. aureus, P. aeruginosa and K. pneumoniae
Replication
replicating
Route
topical
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT04323475Phage Therapy for the Prevention and Treatment of Wound Infections in Burned PatientsUnknownPhase 12022-012023-0112Wound Infection

Recent changes

No changes recorded in its trials yet.

Notes

Phage cocktail sprayed on second-degree burn wounds; phase 1 NCT04323475, where it is called both 'phage cocktail-SPK' and PGX-0100. Separate from BACTELIDE, the same company's pressure-injury product. The registration gives a 14-phage cocktail at 1.4 x 10^8 PFU/mL and names S. aureus, P. aeruginosa and K. pneumoniae as the organisms it is meant to keep out of the wound.

How to cite

PGX-0100 (AXP000239.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000239.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.